DNA Synthesis Market Report: Trends, Forecast and Competitive Analysis to 2035

DNA Synthesis Market

The future of the global dna synthesis market looks promising with opportunities in the commercial and academic research markets. The global dna synthesis market is expected to reach an estimated $11.5 billion by 2035 from $3.3 billion in 2027 with a CAGR of 14.0% from 2027 to 2035. The major drivers for this market are the increasing demand for synthetic genes, the rising adoption in pharmaceutical research, and the growing applications in personalized medicine.

• Lucintel forecasts that, within the type category, gene synthesis is expected to witness higher growth over the forecast period due to rising requests for longer, more complex synthetic gene constructs.
• Within the application category, commercial is expected to witness higher growth over the forecast period due to growing industry use in diagnostic and therapeutic innovation.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to increased biotech IR&D and contract manufacturing in the APAC region.

Emerging Trends in DNA Synthesis Market

Market for DNA synthesis is trending toward more comprehensive services that integrate design, fabrication and validation. This will be the case from 2025 to 2027. Continuous innovations in synthesis have enabled use in various fields including therapeutics, agriculture and industry. Lucintel believes that the ability to perform large scale synthesis and reliability in service will be key to competition.

• Longer Constructs: Synthetic biology companies have been investing to improve their capacity to produce longer genes and pathways. Demand for such large constructs is mainly driven by therapeutics and other industrial synthetics. This creates an opportunity for DNA synthesis companies to focus on producing long constructs.
• Automation: The introduction of robotic processes and automation in construct synthesis has led to a significant reduction in the number of constructs that need to be synthesized by human labor. Companies that have the capacity to synthesize a large number of constructs in an automated manner will gain a competitive edge in the market.
• Artificial Intelligence: Use of artificial intelligence and other tools for designing genetic sequences before synthesizing them is gaining popularity. Integrated DNA synthesis companies will benefit from the competitive edge created by artificial intelligence.
• Regional Supply Diversification: Procurement teams are evaluating whether to work with alternate suppliers across regions (i.e., North America, Europe, and Asia) as a result of Pandemic-related supply chain disruptions. Risk concentration within supplier bases is identified. Dual sourcing and local manufacturing capacities are being assessed, driving investments in regional manufacturing.
• Screening and Compliance: The International Gene Synthesis Consortium's (TIGSC) screening framework and other biosecurity legislations are increasing sequence screenings for supplier due diligence and the maintenance of audit trails. Increased regulation of the market will escalate prices charged by suppliers. However, this will create a competitive advantage for trusted suppliers and facilitate entry of synthetic DNA into the commercial and biomedical markets.

Synthetic Biology is becoming increasingly software and hardware automated. Regulatory frameworks and self-discipline will govern the industry. In the next five years, the ability to consistently integrate biology with other components of a synthetic biology solution will determine a company's profit potential and return on investment.

Recent Developments in the DNA Synthesis Market

The market for DNA synthesis is rapidly growing, especially in research and biomanufacturing. Between 2025 and 2027, expect multiple suppliers to increase their capacity. During this time, further automation and decrease in lead times for software and automation will keep pace with demand. Beyond 2027, Lucintel expects the market to reward integrators of automated platforms.

• Capacity Expansion: In the second quarter of 2025 (May), Twist Bioscience reported more than $191 million in revenue. The company is in the process of expanding its production capacity to meet increasing demand.
• Automated Design: In January 2025, NVIDIA released its BioNeMo software to automate biology. In combination with other software and hardware, the process of designing a synthetic sequence will, in time, be fully integrated with the process of DNA synthesis.
• Commercialization and Advancement of Enzymatic DNA Synthesis: DNA Script continued full scale commercialization of its SYNTAX platform in 2025, with enzymatic synthesis up to 1000 bases. Decentralized production will force centralized service providers to further improve their speed of service, as well as, price.
• Increased Investment in Engineering Biology: Increased funding and investment for the engineering biology sector occurred in 2025, with the UK government's Engineering Biology Mission, allocating £100 million. Continued partnerships between governments and the engineering biology sector will further advance the sector and create opportunities to manufacture synthetics biology products.
• U.S. Biotech Supply Chain Localization and Domestic Sourcing: Changes to U.S. biotech supply chains in 2025, increased the need for biotech suppliers to source domestically. Furthermore, biotech products manufactured in the U.S. may gain competitive advantages in markets with stringent regulation.

Continued focus on speed of service, quality control and regulation will define market leaders in synthetics biology in the coming years. Companies that can manufacture large volumes of synthetic biology products may benefit from first mover advantage, especially in biologics and cell therapy.

Strategic Growth Opportunities in the DNA Synthesis Market

Beyond pilot projects in gene therapies and other fields, the market for synthesis of DNA is expected to take off between 2024 and 2026, with improving biomanufacturing infrastructure and more favorable regulations. According to Lucintel, the market will require more application-specific DNA supply as opposed to cheaper oligonucleotides.

• Manufacturing of Therapeutic Sequences: There is opportunity for DNA/RNA synthesis providers to cater to the need of gene therapy manufacturers for large and circular DNA/RNA for GMP manufacturing. Between 2025 and 2027, it is expected that the FDA will clear more gene therapies for manufacturing. Reliability and reproducibility of supplier's capabilities to manufacture large and circular DNA/RNA will be key during this window.
• Synthetic Biology: DNA synthesis companies have the opportunity to synthesize and manufacture engineered biologicals for their clients. In 2025, the U.S. DOE allocated $36 million for research in Synthetic Biology. In the ensuing years, it is expected that engineered biology will replace current manufacturing processes for chemicals and proteins.
• Agricultural Genomics: Agriculture uses about 70% of the world's freshwater supply. In April 2025, the FAO reported that statistics like these are motivating the development of high-demand crops with genetic resistance to biotic and abiotic stresses. One way to achieve this is through the use of synthetic biology.
• Regional Production Capacity: As of February 2025, the EU's biotech strategy empowered the region to invest about €1 billion into the space. Concurrently, automation in genetic engineering and editing facilitates the reduction of lead times associated with biotech products. This automation is expected to drive the biotech industry in the direction of just-in-time deliveries and traceability.
• Customized Workflows and Automation: Clients are increasingly willing to enter long-term agreements as automation and other integration services begin to dominate the genetic engineering market.

Many customers will continue to evaluate biotech syndetic based on the individual contracts they award, however the market is expected to expand. Most clients will base their evaluation of biotech synthetics on price, quality, and the supplier's adherence to regulations. Given ongoing biosafety concerns and the capital-intensive nature of the biotech market, achieving a dominant position will require a combination of automation and scalable services.

DNA Synthesis Market Drivers and Challenges

Rising technology and biotech applications, falling costs and larger sustainability and regulatory impacts shape the dna synthesis market. DNA synthesis is pivotal to the advancement of the fields of medicine and research. Lucintel has reported that synthetic biology and related fields rely heavily on the performance of service providers to meet growing market demands.

The factors responsible for driving this market include:

• Increasing Demand for Synthetic Biology: The increasing demand for customized biomolecules is primarily driven by the emerging field of synthetic biology. Other fields such as diagnostics and agriculture are also fueling this growth. The increased focus on personalized medicine has led to an elevated need for advanced and innovated biological systems. The synthesis of new and complex biological systems requires the assembly of thousands of genetic building blocks. These building blocks are extremely small and increases the need for automated DNA and RNA synthesis. Concurrently, regulatory bodies have changed their focus to increase and simplify access to clinical trials. It is expected that between 2022 and 2025, the number of ongoing clinical trials will double. This increasing demand will stimulate the DNA and RNA synthesis market.
• The number of commercial laboratories offering synthetic DNA construction services has grown rapidly. Many have developed automated systems to improve the accuracy and speed of DNA synthesis. Traditional chemistry and biology processes are usually less accurate and faster than synthetic biology processes; however, the automation of processes and use of artificial intelligence in synthetic biology are closing the gap. In March 2025, automated laboratory platforms were able to execute hundreds of reactions in a single run. The platforms are expected to continue to evolve to support larger and more complex nucleic acid synthesis and significantly reduce the cost of nucleic acid synthesis.
• Increased demand and funding from government organizations to develop new vaccines, improve technologies in advanced manufacturing and biosecurity, has increased the private and public research infrastructure. These investments have enabled more companies to outsource the production of DNA. In the US, the federal government continued to implement a program in 2025 to increase biosecurity by reviewing the orders of synthetic nucleic acids. In the next several years, grants and contracts will likely lead to an increase in research and synthesis of DNA by various organizations, but companies will need to screen sequences to qualify for government contracts.
• Innovations in DNA Synthesis: Conventional chemical DNA synthesis involves labor- and resource-intensive processes, including the use of hazardous reagents, solvents, and plastics. Automation and the miniaturization of DNA synthesis have largely been limited by the high cost of consumables and chemicals, and large energy inputs. Enzymatic approaches to DNA synthesis continue to improve, but processes that require the least input to achieve DNA synthesis will likely dominate the field in the near future. In the field, customers base supplier evaluations on environmental impact, waste, and energy use. To remain competitive in the market, suppliers will need to make adjustments to consumables and production technologies. Investments in improved chemistry and production facilities will allow suppliers to produce greener consumables.
• Advancements in DNA Synthesis: Reduced costs for the synthesis of DNA have allowed smaller biotech companies, as well as academic laboratories, to perform next-generation sequencing. High-throughput sequencing has significantly reduced costs for synthesizing long, complex DNA sequences. In 2025, several biotech companies and academic laboratories purchased synthetic DNA over the Internet, and some companies integrated automated online ordering and quoting systems to further reduce the time required for customer purchases. Price reductions for synthesis will stimulate greater use of the technology, smaller DNA sequences, and faster turnaround times. Further, increased competition will result in higher levels of outsourcing.

The challenges specific this market include:

• Long, Repetitive, Toxic, or Structurally Difficult Sequences: The commercially available enzymes for synthesizing genetic sequences are not reliable for long, repetitive sequences and structurally difficult sequences. Therefore, synthesizing repetitive and toxic sequences still require multiple enzymes. Hence, these sequences remain expensive and challenging to manufacture. Errors and inaccuracies in producing a genetic sequence can lead to redesign of the sequence and the need for additional testing. In June 2025, a number of service providers continued to implement a limit on the length of genetic sequences and/or additional review of sequences to be synthesized. These challenged service constraints are expected to slow the adoption of these services by small biotechnology companies. However, improving the reliability and reducing the cost of enzymes and other bio-chemicals may remove market constraints in the near term.
• Manufacturing Synthetic DNA: Although Synthetic DNA has many beneficial uses, it raises ethical concerns because it can also be used to reconstruct biologic agents. Providers face challenges with product liability. In July 2025, many companies reported the need for improved international harmonization of DNA screening. Based upon the U.S. policies, agencies expected that DNA sequences longer than 200 base pairs would be screened. Responsible suppliers have the opportunity to gain a competitive edge through the adoption of best practices and credible DNA screening.
• DNA Synthesis: It is a complex process requiring a number of enzymes, chemicals and materials, sophisticated equipment, trained personnel and reliable delivery systems. Unforeseen problems with the quality and/or timely delivery of raw materials can adversely affect the quality and consistency of a supplier's product. In August 2025, biotechnology companies continued efforts to manufacture products in more than one geographical location to reduce the risk of reliance on international transportation and suppliers. Because of the increasing requirements of the products and the demand for those products, biotechnology companies will be required to develop and utilize multiple supplier and manufacturing locations, as well as increase and enhance their validation and testing, within the next 3 to 5 years.

Advances in biotechnology will continue to make DNA synthesis a more automated and integrated process which will create more opportunities in the market. The impact of investments in research and development, as well as the continuing focus on improving the efficiency of manufacture and use of biotechnology to reduce the environmental impact, will create additional opportunities in the market. While it will be easier to manufacture more and varied products, the inherent complexity of many biotechnology processes may make it slower and more costly to manufacture biotechnology products. In the future, the biotechnology industry will benefit from further integration of biotechnology with other industries.

List of DNA Synthesis Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies dna synthesis market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the dna synthesis market companies profiled in this report include-

• GenScript Biotech
• Thermo Fisher Scientific
• IDT
• Eurofins Scientific
• DNA 2.0

DNA Synthesis Market by Segment

The study includes a forecast for the global dna synthesis market by type, application, and region.

DNA Synthesis Market by Type [Value ($B) from 2019 to 2035]:

• Oligonucleotide Synthesis
• Gene Synthesis

DNA Synthesis Market by Application [Value ($B) from 2019 to 2035]:

• Commercial
• Academic Research

DNA Synthesis Market by Region [Value ($B) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the DNA Synthesis Market

The dna synthesis market is transitioning from providing customized research services to offering large-scale automated DNA synthesis services. This is due to the recently introduced government policies and the increasing investment in therapeutics and other drugs influenced by genetics. In the 2025-2027 period, the Lucintel analysis predicted that several countries would enhance their capacities in this field.

• United States: The recommended policies and measures of the National Security Commission on Emerging Biotechnology were implemented by several federal agencies. Meanwhile, companies focused on automating and expanding their biomanufacturing capacities. As a result, some companies in the U.S. are expected to become major suppliers of DNA synthesis in the coming years.
• China: In 2025, the Chinese government extended and expanded the existing programs on biotechnology and industry. As a result, genetic synthesis, as well as next-generation sequencing and biologics, services benefitted from the latest investments. Furthermore, the local integrations and procurements by the Chinese pharmaceutical and agro-biotech industries positive impacted the domestic DNA synthesis services.
• Germany: Germany is expected to further strengthen its position as a major production center in Europe, as Germany is home to Eurofins' life science facilities and the EU strengthens its framework to secure its biolabs. Eurofins reported revenues of around 7.1 billion euros in 2025. With higher EU regulatory and compliance standards and the availability of contract service facilities in the region, the need for reliable, high quality DNA manufacturing and biomanufacturing will increase.
• India: India's BioE3 policy, in combination with increased government funding in biotechnology, promoted the establishment of indigenous biomanufacturing facilities in 2024 and 2025. The Government of India committed 100,000 crore rupees (~10 billion USD) to the IndiaAI mission in 2024. Public investment in computational science and design will improve molecular synthesis.
• Japan: Japan, in collaboration with big Pharma, continues its focus on building its precision medicine ecosystem. Takeda aimed to spend over 600 billion yen in 2025 to develop advanced biologics and other areas of genetic medicine. The high level of investment strengthened the ecosystem to synthesize DNA and energized the pharma industry to establish facilities for the production of precision medicines.

Features of the Global DNA Synthesis Market

• Market Size Estimates: dna synthesis market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: dna synthesis market size by type, application, and region in terms of value ($B).
• Regional Analysis: dna synthesis market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the dna synthesis market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the dna synthesis market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the dna synthesis market by type (oligonucleotide synthesis and gene synthesis), application (commercial and academic research), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?